Access and Evidence
Red Blood for the French Healthcare System
With a stark change in public policy, the French healthcare system is facing a major overhaul. At stake is the relationship between big pharma and the French administration.
More Access and Evidence Articles
Access and Evidence
Big Pharma - Time For Change in India Pricing Strategy
Big Pharma should rethink their price strategy for the emerging markets as they continue to develop their business overseas with countries like India.
Access and Evidence
The Secret to Payer Access? Communication is Key
An exclusive video from our flagship event, Barcelona 2012 explains there is more to a relationship with payers than sales pitches...
Access and Evidence
Pharma market access and product development
Janice Haigh, practice leader, market access Europe at Quintiles Consulting, on why pharma should be thinking about market access from the early stages of product development
Access and Evidence
Pharma market access in Germany
Peter Mansell explores what Germany’s Act to Reform the Market for Medicinal Products means for market access
Access and Evidence
Patients groups and market access
Andrew Tolve outlines the pharma industry’s growing need for local insights and local patient partnerships to gain market access
Access and Evidence
Market access: Pharma and the definition of value
Jan Stojaspal explores the role of value-based pricing in gaining market access
Access and Evidence
Pharma, market access, and the need for network intelligence
Jan Stojaspal investigates how network intelligence can improve sales productivity and smooth market access
Access and Evidence
Market access and the need for stakeholder-centricity
Jan Stojaspal examines how pharma can build mutually advantageous partnerships within a changing stakeholder environment
Access and Evidence
Dr. Bates’ Talkback: The impact of a ‘virtual’ structure on market access
Dr. Andree K. Bates considers the implications of a ‘virtual’ pharma structure of key aspects of market access